Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Octreotide Acetate in Microspheres
Octreotide in Microspheres · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Octreotide Acetate in Microspheres | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Octreotide Acetate in Microspheres 20 mg | EXPERIMENTAL | 20 mg will be administered im once every 4 weeks |
| Octreotide Acetate in Microspheres 30 mg | EXPERIMENTAL | 30 mg will be administered im once every 4 weeks |
| Name | Type | Description |
|---|---|---|
| Octreotide Acetate in Microspheres | DRUG | - |
| Placebo | DRUG | - |
| Octreotide Acetate in Microspheres 20 mg | DRUG | - |
Inclusion Criteria: * Males and females with type 1 and type 2 diabetes mellitus * Moderately severe or severe NPDR or mild PDR in at least one eye: * with an Early Treatment Diabetic Retinopathy Study (ETDRS) visual score of \> 35 letters; and * not previously treated with scatter photocoagul...
Top 6 of 8 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Ocular Therapeutix Inc | OCUL | 1 | PHASE3 | OTX-TKI |
| AbbVie, Inc. | ABBV | 3 | PHASE2 | Surabgene Lomparvovec |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | MK-8748 |
| Jaeb Center for Health Research | RHHBY | 3 | PHASE3 | Faricimab, RO7663498 |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-150 |
| Adverum Biotechnologies, Inc. | ADVM | 1 | - | ADVM-022 |
Octreotide in Microspheres is being developed for the treatment of diabetic retinopathy, an eye condition that can affect people with diabetes. It is an investigational therapy and has been studied in Phase 3 clinical trials. The drug is not approved for this use.
Octreotide in Microspheres targets somatostatin receptors SSTR1, SSTR2, SSTR3, SSTR4, and SSTR5. It acts as an agonist at these receptors. By binding to these targets, it is designed to modulate signaling pathways that may be involved in diabetic retinopathy.
Octreotide in Microspheres is being developed by Novartis AG, which trades under the ticker symbol NVS. Novartis is a global pharmaceutical company. The drug is in Phase 3 development for diabetic retinopathy.
Octreotide in Microspheres is in Phase 3 clinical development for diabetic retinopathy. Two Phase 3 trials have been completed. The drug is investigational and has not been approved by the FDA for any indication.
Octreotide in Microspheres has been studied in two completed Phase 3 trials: NCT00131144, which enrolled 583 patients, and NCT00130845, which enrolled 312 patients. Both trials were conducted in the United States in adults with diabetic retinopathy. Both were randomized, double-blind, and placebo-controlled.
Yes, Octreotide in Microspheres is also known as Octreotide Acetate in Microspheres. The 20 mg formulation is referred to as Octreotide Acetate in Microspheres 20 mg. These names refer to the same investigational product being developed by Novartis for diabetic retinopathy.